Asian J. Research Chem. 3(3): July- Sept. 2010
www.ajrconline.org
ISSN 0974-4169 RESEARCH ARTICLE
A Simultaneous Estimation of Perindopril and Losartan in Solid Dosage Forms by UV Spectrophotometry. R. Vijayalakshmi, S. Archana and M.D. Dhanaraju*
Research Lab., GIET School of Pharmacy, NH-5 Chaitanya Nagar, Rajahmundry-533294. *Corresponding Author E-mail:
[email protected].
ABSTRACT:
Perindopril and losartan are used in combination for treatment of hypertension. The present work deals with a simple spectrophotometric method development for simultaneous estimation of perindopril (PRL) and losartan (LSN) in two component–formulation. First order derivative spectrophotometric method is adopted to eliminate spectral interference. The method obeys beer’s law in the concentration ranges employed for evaluation. To determine the sampling wave length, 10mcg/ml of PRL and LSN were scanned from 200-350nm. The wavelengths were found to be 219 nm for PRL, where LSN showed zero crossing point and 214nm for LSN, where PRL showed zero crossing point in First order derivative spectroscopy. The recovery studies confirmed accuracy of proposed method and low values of standard deviation confirmed precision of the method. The method is validated as per ICH guidelines.
KEYWORDS: Perindopril, Losartan, First order derivative spectroscopy. INTRODUCTION:
Perindopril, (2S)-2-{(1S)-2-carbethoxy butyl amino}-1-oxo propyl-(2s, 3as, 7as)-1-per hydro indole-2-carboxylic acid1 is one of the ACE2 inhibitor used in the treatment of hypertension and heart failure. The drug is official in Martindale; the extra pharmacopoeia. Extensive literature survey reveals that the determination of drug is not official in any pharmacopoeia and therefore requires much more investigation. Several analytical methods have been reported for the estimation of perindopril are Initial rate method3, Amperometric method4, Spectrophotometric method5, 6, Potentiometric method7, Liquid Chromatography8, Gas Chromatography9, High performance Liquid Chromatography10, Reverse phase Liquid Chromatography11. Losartan , 2-n-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]-imidazole-5methanol mono potassium salt is a highly selective , orally active, non-peptide angiotensin II receptor antagonist indicated for the treatment of hypertension 12. The determination of losartan has been carried out in tablets by HPLC, capillary electrophoresis and super-critical fluid Chromatography13, 14. In urine by Gas Chromatography-mass spectrometry15 and simultaneously with its active metabolite in biological fluids by HPLC.16-20 Received on 09.01.2010 Accepted on 20.03.2010
Modified on 14.02.2010 © AJRC All right reserved
MATERIALS AND METHOD:
Instrument: Spectral measurements were made on an Elico UV-visible spectrophotometer (SL164) with 1cm matched quartz cells. REAGENTS AND CHEMICALS: Losartan and Perindopril were supplied by Aurubindo Pharma Ltd. All chemicals were of analytical reagent grade. METHOD: Stock solutions were prepared in 0.1N NaOH. Six mixed working standards solutions were prepared by diluting the stock solution by the same solvent in concentration range of 10-30 mcg/ml for PRL and 1-5 mcg/ml for LSN. PRL and LSN were initially scanned for determining sampling wavelength in the range of 200-350nm. To overcome spectral interference from other drug, first order derivative spectra (figure-1) of both the drugs were recorded. It was observed that PRL showed dA /d zero at 214nm in contrast to LSN that has considerable dA/d at this wavelength. Further LSN has zero dA/d at 219nm while at this wavelength PRL has significant dA/d . Therefore these two wave lengths were employed for the estimation of PRL and LSN without any interference. The calibration curves were plotted at these two wave lengths of concentrations against dA/d with in the above mentioned range.
Asian J. Research Chem. 3(3): July- Sept. 2010; Page 571-573
571
Asian J. Research Chem. 3(3): July- Sept. 2010 Figure-1. Overlain spectra of PRL and LSN
TABLE 3: RESULTS OF RECOVERY STUDIES Analyte % Recovery estimated (Mean ± SD*) PRL 100.22±0.8064 LSN 100.22±0.8064 SD: Standard deviation, RSD: Relative Standard deviation, average of six determinations.
RSD* 0.8736 0.8828 *Denotes
CONCLUSION:
The method used is simple, rapid and accurate, does not involve any extraction procedures, low value of standard deviation showed that the method is precise and high percentage of recovery as shown in table 3 indicates the method is accurate.
REFERENCES: 1.
2. 3.
Analysis of commercial formulation: Average weight of twenty tablets was determined .Powder equivalent to 50 mg PRL and 4mg of LSN was taken and added in 60 ml of solvent system, sonicated for 10 min, after sonication the volume was made up to 100ml. 1ml of this stock solution was diluted to 10ml to get concentration equal to 10 mcg/ml of PRL and 5 mcg/ml of LSN. The solution was scanned in the range of 200-350nm against solvent system as blank. The spectra obtained were converted to first order derivative, absorbances were noted and concentrations were determined from regression equations generated from calibration graph.
4.
5. 6.
7. 8.
RESULTS AND DISCUSSION:
Sampling wave lengths were determined from scanning individual drug samples in 200-350nm range. Sampling 9. wave lengths were 219 nm and 214 nm for PRL and LSN respectively in first order mode. For this method equations 10. generated were 0.025x-0.0794 (r2=0.9987) and 0.23x2 0.0184 (r =0.9985) for PRL and LSN respectively. Linearity of proposed method was found to be 1030mcg/ml for PRL and 1-5mcg/ml for LSN. Results of analysis of commercial formulation were reported in Table 11. 1, results of precision studies and recovery studies were reported in Table 2 and 3 respectively. TABLE 1: Results of analysis of commercial formulation Analyte Label claim % Label claim RSD* (mg/tab) estimated (Mean± SD*) PRL 10 99.82±0.8064 0.8932 LSN 5 100.02±0.5064 0.8956 SD: Standard deviation, RSD: Relative Standard deviation, *Denotes average of six determinations. TABLE 2: Results of precision studies. Analyte Label Amount % Label claim ± claim (mg) Estimated (mg) SD* PRL 50 49.5 99.82±0.6064 LSN 4 4.01 100.22±0.7064 SD: Standard deviation, *Denotes average of six determinations.
12.
13.
14.
572
The Merck index, 14 th edition, an encyclopedia of chemicals, drugs and biological; Division of Merck and co., inc. Rahway, New jersey, U.S.A, 1983,7170. Sweetman S.C, Eds in; Martindale : The Extra pharmacopoeia., Royal pharmaceutical society, 34 th edition , The pharmaceutical press, London, 2002. Rahman N, Nishat and Kashif M. Optimized and validated initial rate method for determination of perindopril, Erbrumine in tablets. Chem. Pharm. Bull. 2006; 54: 33-36. Stefan RI, Vanstaden JF and Aboul-Enein HY. Determination of S-perindopril using a flow injection system with an amperorometric biosensor. Sensors and Actuators B chemical. 1999; 54(9): 261-265. Utility of certain pi-receptors for the spectrophotometric determination of perindopril J Pharm Biomed Anal.1998; 17(8): 1267-1271. Harlikar J.N and Amlani A.M. Simultaneous Determination of perindopril, Indapamide, Ramipril, Trandopril, in Pharmaceutical formulations using Reverse phase Liquid Chromatography . Res J of Chem and Environment. 2003;7(4). Stefan RI, Jacobus F, Staden V and Aboul-enein HY. Sperindopril assay using a Potentiometric, enantioselective membrane electrode chirality. 1999; 11(8): 631-634. Abdalla AE, Samia MM and Elgawish MS. Development and Validation of LC method for Simultaneous Determination of Two Binary Mixtures Contaning Indapamide, Chromatographia, 2008; 67: 837-840. Lin SJ, Wu HL, Chen SH and Wen YH. Derivitization-gas chromatographic determination of perindopril. Anal. Letters. 1996; 29(10): 1751-1762. Simoncic Z, Roskar R, Gartner A, Kogej K and Kmetec. The use of micro calorimetry and HPLC for the determination of degradation kinetics and thermodynamic parameters of perindopril Erbumine in aqueous solutions. Int J of pharmaceutics. 2008; 356 (1-2): 200-205. Polinko M, Riffel K, Song H and Man- Wai Lo. Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/ tandem mass spectrometry. J Pharma and Biomed Anal. 2003; 33: 73- 84. Williams RC, Alasandro MS, Fasone VL, Boucher RJ and Edwards JF. Comparison of liquid chromatography, capillary electrophoresis and super-critical fluid chromatography in the determination of Losartan Potassium drug substance in Cozaar tablets. J Pharma Biomed Anal. 1996; 14 (11): 15391546. Mccarthy KE, Qingxi Wang Tsai EW, Gilbert RE, Brooks MA. Determination of losartan and its degrades in COZAAR tablets by reversed-phase high-performance thin-layer chromatography. J Pharm Biomed Anal. 1998; 17: 671–677. Maurer H.H, Kraemer T and Arlt JW. Screening for the Detection of Angiotensin-Converting Enzyme Inhibitors, Their Metabolites, and AT II Receptor Antagonists. Ther. Drug Monit. 1998; 20: 706–713.
Asian J. Research Chem. 3(3): July- Sept. 2010 15. Furtek CI and Lo MW. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chroma: Biomed Appli. 1992; 573 (2): 295-301. 16. Lee H, Shim HO and Lee HS. Simultaneous Determination of Losartan and Active Metabolite EXP3174 in Rat Plasma by HPLC with Column Switching. Chromatographia. 1996; 42: 39– 42. 17. El Walily AFM, Belal SF and Heaba EA. An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by highperformance liquid chromatography with fluorescence detection J Pharma Biomed Anal. 1997; 15 (7): 1021-1029. 18. Farthing D, Sica D, Fakhry I, Pedro A, Gehr TWB. Simple high-performance chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate. J Chromatogr B 1997; 704: 374-378. 19. Soldner A, Spahn-Langguth H and Mutschler E. HPLC assays to simultaneously determine the antagonist losartan as well as its main and angiotensin-AT1 active metabolite EXP 3174 in biological material of humans and rats. J Pharma Biomed Anal. 1998; 16 (5): 863-873. 20. Soldner A, Spahn-Langguth H, Palm D and Mutschler E. A radio receptor assay for the analysis of AT - receptor antagonists: Correlation with 1complementary LC data reveals a potential contribution of active metabolites. J Pharma Biomed Anal. 1998; 17(1): 111-124.
573
